Herbalife (HLF) Earnings Date & Reports

Key Takeaways

• Herbalife reported third-quarter 2026 net sales of $1,350.2 million, up 6.0% year over year and its fifth consecutive quarter of top-line growth.
• Adjusted diluted earnings per share (EPS) came in at $0.64, above the consensus estimate of $0.62 and up $0.14 from the prior-year quarter.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $182 million, exceeding the company's guidance range of $160 million to $180 million.
• Worldwide volume rose 8.6% year over year, with India driving outsized growth as net sales there climbed roughly 39% on a reported basis.
• Year-to-date operating cash flow reached $298 million, up about 27% versus the first nine months of 2025.
• For more context on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages for additional insight.
• You can also explore Trending AI Robots to see how AI-driven strategies are being applied across the market.

Earnings Context and Why It Matters

Herbalife's third-quarter report matters because it tests whether the company's multi-year turnaround can keep compounding. After a prolonged stretch of uneven growth and restructuring, the business has now strung together five straight quarters of year-over-year sales expansion. Investors are watching closely to see whether that recovery is broad-based or overly dependent on a single region. The results also offer a window into distributor momentum, pricing power, and cash generation, all of which shape how the market values the stock against its elevated debt load.

Reported Results

For the third quarter ended September 30, 2026, Herbalife reported net sales of $1,350.2 million, up 6.0% from $1,273.7 million a year earlier and above the consensus revenue estimate of roughly $1.32 billion. Adjusted diluted EPS was $0.64, beating the consensus estimate of $0.62. On a GAAP (Generally Accepted Accounting Principles) basis, diluted EPS was $0.55, up from $0.42 in the prior-year period.

Net income attributable to Herbalife was $58.8 million, up 36% year over year. Adjusted EBITDA rose to $182 million, above the company's guidance range of $160 million to $180 million, with adjusted EBITDA margin expanding 70 basis points to 13.5%. Gross profit margin was 77.3%, down 40 basis points year over year, reflecting country mix and sourcing costs partly offset by pricing benefits. Worldwide volume increased 8.6%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven moves like Herbalife's, it offers a structured way to monitor related setups and sector momentum.

Market Reaction and Investor Sentiment

Shares of Herbalife moved higher following the release, with investors responding positively to an earnings beat and revenue that exceeded consensus. The market's reaction appeared driven by the company's fifth consecutive quarter of growth, above-guidance adjusted EBITDA, and strengthening cash flow. India's outsized contribution was a focal point, with some attention on whether the country's growth is sustainable as the company laps a favorable comparison from the prior year. Foreign-exchange (FX) headwinds remained a factor but did not derail the broadly upbeat tone.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether Herbalife can sustain its growth streak as it laps a strong prior-year comparison in India. The company has signaled that it expects continued growth in that market even after lapping the change in India's GST (Goods and Services Tax) that boosted prior-period results.

Margin trends will be another key focus. While adjusted EBITDA margin expanded year over year, gross margin declined modestly on country mix and self-manufacturing costs. The balance between pricing benefits and these cost pressures will help determine whether profitability gains continue.

Cash generation and debt reduction also remain central themes. With year-to-date operating cash flow up about 27%, investors will monitor leverage progress and any capital-allocation updates. Finally, strategic initiatives, including the expansion of the Bioniq premium wellness brand and broader distributor ecosystem investments, may provide additional catalysts in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations